Views:12 Author:Site Editor Publish Time: 2020-01-28 Origin:Site
On March 13, at Patheon's Linz Plant (formerly DSM) in Austria, Cheng Dang, a researcher from Fudan University, gave a "Pharmaceutical Process Development: Opportunities and Challenges" report to Patheon's R & D technical team, which was highly praised by Patheon's R & D technical team , Causing a lively discussion.
Dr. Peter, Chief Technical Consultant of Patheon, introduced that the company was established in 1939 and has been committed to producing pharmaceutical intermediates and fine chemicals; it was acquired by DSM DSM in the Netherlands in 1996; DSM acquired Canadian pharmaceutical manufacturer Patheon in 2014 , Which merged with its own pharmaceutical business to form Patheon.
Later, under the leadership of Dr. Peter, we visited the entire factory, and Dr. Peter introduced the situation of the production workshop. As early as 2007, the factory adopted the Plantrix industrial continuous flow reactor to achieve continuous production of pharmaceutical intermediates. In a workshop of less than 20 m2, 12 MR500s were running simultaneously to achieve an annual output of 10,000 tons of nitrated intermediates. The inspection provided valuable experience and confidence for the microchannel industrialization center established by Diezhi Medicine and Juxian Medicine in Taizhou.